7Syrjanen S,Shabalova IP,Petrovichev N,et al.Human papillomavirus testing and conventional Pap smear cytology as optional screening tools of women at different risks for cervical cancer in Countries of the former Soviet Union.J Low Genit Tract Dis,2002,6:97-110.
8Bosch FX,Manos MM,Munoz N,et al.Prevalence of human papillomavirus in cervical cancer:a worldwide perspective.International biological study on cervical cancer (IBSCC) Study Group.J Natl Cancer Inst,1995,87:796-802.
9Vizcaino AP,Moreno V,Bosch FX,et al.International trends in incidence of cervical cancer:Ⅱ.Squamous-cell carcinoma.Int J Cancer,2000,86:429-435.
10Munoz N,Bosch FX,de Sanjose S,et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer.N Engl J Med,2003,348:518-527.
1Sakuragi N.Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer[J].Int J Clin Oneol,2007,12(6): 165-175.
2Nagy VM,Buiga R,Brie I,et al.Expression of VEGF,VEGFR,EGFR,COX-2 and MVD in Cervical carcinoma, in relation with tile response to radio- chemotherapy[J].Rom J Morphol Embryol,2011,52(1 ):53-59.
3Suh DH,Kim JW, Aziz MF,et al.Asian society of gynecologic oncology workshop 2010[J].J Gynecol Oncol,2010,21 (3): 137-150.
4Polcher M,Rudlowski C,Friedrichs N,et akin vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovariancancer[J].BMC Cancer,2010,10:137.
5Biedka M,Makarewicz R,Marszalek A,et al.Labeling of microvessel density, lymphatic vessel density and potential role of proangiogenic and lymphangiogenic factors as a predictive/prognostic factors after radiotherapy in patients with cervical cancer[J].Eur Gynaecol Oncol,2012,33(4):399-405.
6Ke-Jin Huang,Li-Hua Sui.The relevance and role of vascular endothelial growth factor C,matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer[J].Med Oncol,2012,29:318-323.
